A Conversation with Dr. Jason Sicklick
In this interview with researcher & surgical oncologist Dr. Jason Sicklick shares about his passion for SDH-deficient GIST research.
21
12, 2022
19
02, 2021
GIST Expert Dr. Jason Sicklick & Team Release New Study on What Drives GIST
In a recent study, researchers at University of California San Diego School of Medicine identified new therapeutic targets that could lead to new treatment options for patients. The study, published in the February 18, 2021 online edition of Oncogene, found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.
19
05, 2020
Dr. Jason Sicklick Receives Grant for Temozolomide Phase II Trial
The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
15
12, 2022
It’s Time to Tell The Stories: Our Good News – Research – Dr. Sicklick
Our Good News Holiday Campaign is the culmination of our year of "Time to Tell the Stories 2022." In this series, we celebrate the connections, the celebrations, the events and milestones that we’ve been privileged to be a part of this year. Dr. Jason Sicklick discusses his research in SDH-deficient GIST.
10
08, 2022
Life Fest 2022: The Role of Surgery in GIST Treatment/Neoadjuvant & Adjuvant Therapy
Dr. Jason SIcklick, UC San Diego Moores Cancer Center presented The Role of Surgery in GIST Treatment/Neoadjuvant & Adjuvant Therapy at Life Fest 2022 in New Orleans.
22
09, 2021
New Research Lab Dedicated to GISTer
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
3
12, 2020
Custo efetividade do teste genético para pacientes recém diagnosticados com GIST
Em um artigo publicado em 29 de setembro de 2020, na revista "JAMA Network Open", o Dr. Jason Sicklick, Moores Cancer Center, UCSD, e colegas relataram que o teste genético é custo-efetivo e benéfico para pacientes com GIST metastático recém-diagnosticados. .
15
10, 2020
Pruebas genéticas costo efectivas para GIST recién diagnosticados
En un artículo publicado el 29 de septiembre de 2020 en la revista “JAMA Network Open”, Dr. Jason Sicklick, Moores Cancer Center, UCSD y sus colegas informaron que las pruebas genéticas son costo efectivas y beneficiosas para los pacientes recién diagnosticados con GIST metastásico.
28
09, 2020
Genetic Testing Cost Effective for Newly Diagnosed GIST
UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.
14
07, 2020
RARE Partnership in Advocacy, Funding, and Research for Gastrointestinal Stromal Tumor
Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.
Need a new search?
If you didn't find what you were looking for, try a new search!